Human Monoclonal Antibodies as Candidate Therapeutics Against Emerging Viruses and HIV-1

被引：0

作者：

Zhongyu Zhu ^{[1
]}

Ponraj Prabakaran ^{[1
,2
]}

Weizao Chen ^{[1
]}

Christopher CBroder ^{[3
]}

Rui Gong ^{[4
]}

Dimiter SDimitrov ^{[1
]}

机构：

[1] Protein Interactions Group, National Cancer Institute, National Institutes of Health

[2] Basic Research Program, Science Applications International Corporation-Frederick, Inc

[3] Department of Microbiology and Immunology, Uniformed Services University

[4] Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of

来源：

Virologica Sinica | 2013年 / 28卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.

引用

页码：71 / 80

页数：10

共 50 条

[31] Model systems of human immunodeficiency virus (HIV-1) for in vitro efficacy assessment of candidate vaccines and drugs against HIV-1 [J].

Rudometova, N. B. ;

Shcherbakov, D. N. ;

Rudometov, A. P. ;

Ilyichev, A. A. ;

Karpenko, L. I. .

VAVILOVSKII ZHURNAL GENETIKI I SELEKTSII, 2022, 26 (02) :214-221

[32] Competitive study of monoclonal antibodies against the HIV-1 Gp41 core structure [J].

Usami, O ;

Xiao, P ;

Ling, H ;

Hattori, T .

MICROBIOLOGY AND IMMUNOLOGY, 2006, 50 (02) :131-134

[33] An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1 [J].

Kumar, Sanjeev ;

Singh, Swarandeep ;

Luthra, Kalpana .

ACS OMEGA, 2023, :7252-7261

[34] Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19 [J].

Chen, Junsen ;

Huang, Rui ;

Nie, Yiwen ;

Wen, Xinyue ;

Wu, Ying .

VIROLOGICA SINICA, 2020, 35 (06) :713-724

[35] Monoclonal antibodies from patient with acute HIV-1 infection [J].

Chen, W. ;

Xiao, X. ;

Streaker, E. ;

Wang, Y. ;

Markowitz, M. ;

Haynes, B. .

RETROVIROLOGY, 2009, 6

[36] Monoclonal antibodies to an HIV-1 group O envelope recombinant [J].

Scheffel, JW ;

Ziemann, R ;

Hawksworth, D ;

Tyner, J ;

Hickman, RK ;

Hackett, J .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 22 (03) :221-227

[37] Understanding the mechanism of HIV-1 protease inhibition by monoclonal antibodies [J].

Gupta, Suchetana ;

Balasubramanian, Sangeetha ;

Senapati, Sanjib .

JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2021, 103

[38] Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success [J].

Pablo Jaworski, Juan ;

Vendrell, Alejandrina ;

Matias Chiavenna, Sebastian .

FRONTIERS IN IMMUNOLOGY, 2017, 7

[39] CCR5 monoclonal antibodies for HIV-1 therapy [J].

Olson, William C. ;

Jacobson, Jeffrey M. .

CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) :104-111

[40] Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19 [J].

Junsen Chen ;

Rui Huang ;

Yiwen Nie ;

Xinyue Wen ;

Ying Wu .

Virologica Sinica, 2020, 35 (06) :713-724

← 1 2 3 4 5 →